Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Serum tau and neurological outcome in cardiac arrest

Research output: Contribution to journalJournal articleResearchpeer-review


  1. MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy

    Research output: Contribution to journalReviewResearchpeer-review

  2. A New Glycogen Storage Disease Caused by a Dominant PYGM Mutation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Neuroinflammatory markers associate with cognitive decline after major surgery: findings of an explorative study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Hypersensitivity to Calcitonin Gene-Related Peptide in Post-Traumatic Headache

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Niklas Mattsson
  • Henrik Zetterberg
  • Niklas Nielsen
  • Kaj Blennow
  • Josef Dankiewicz
  • Hans Friberg
  • Gisela Lilja
  • Philip S Insel
  • Christian Rylander
  • Pascal Stammet
  • Anders Aneman
  • Christian Hassager
  • Jesper Kjaergaard
  • Michael Kuiper
  • Tommaso Pellis
  • Jørn Wetterslev
  • Matthew P Wise
  • Tobias Cronberg
View graph of relations

OBJECTIVE: To test serum tau as a predictor of neurological outcome after cardiac arrest.

METHODS: We measured the neuronal protein tau in serum at 24, 48, and 72 h after cardiac arrest in 689 patients in the prospective international Target Temperature Management trial. The main outcome was poor neurological outcome, defined as Cerebral Performance Category 3-5 at 6 months.

RESULTS: Increased tau was associated with poor outcome at 6 months after cardiac arrest (median 38.5 [IQR 5.7-245] ng/L in poor versus 1.5 [0.7-2.4] ng/L in good outcome, for tau at 72 h, p<0.0001). Tau improved prediction of poor outcome compared to using clinical information (p<0.0001). Tau cut-offs had low false positive rates (FPR) for good outcome while retaining high sensitivity for poor outcome. For example, tau at 72 h had FPR 2% (95% CI 1-4%) with sensitivity 66% (95% CI 61-70%). Tau had higher accuracy than serum NSE (the area under the receiver operating characteristic curve was 0.91 for tau versus 0.86 for NSE at 72 hours, p=0.00024). During follow-up (up to 956 days), tau was significantly associated with overall survival. The accuracy to predict outcome by serum tau was equally high for patients randomized to 33°C and 36°C targeted temperature after cardiac arrest.

INTERPRETATION: Serum tau is a promising novel biomarker for prediction of neurological outcome in patients with cardiac arrest. It may be significantly better than serum NSE, which is recommended in guidelines and currently used in clinical practice in several countries to predict outcome after cardiac arrest. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalAnnals of Neurology
Issue number5
Pages (from-to)665-675
Publication statusPublished - 2017

    Research areas

  • Journal Article

ID: 51799821